Clinical Trial Update: A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

A Phase 1 study assessed the impact of tofacitinib (CP-690,550) on kidney function in patients with active rheumatoid arthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 1 | Status: COMPLETED | Results posted: 2014-04-02